The purpose of this study is to determine the effect of the ASA404 infusion rate and co-administrating ASA404 with paclitaxel + carbopaltin chemotherapy regimen or docetaxel on the pharamcokinetics (PK) of free and total ASA404.

Inclusion Criteria:

• Patients having histologically-proven solid tumors, who are either refractory to standard chemotherapy
• Patients whom chemotherapy with an investigaional agent in combination with docetaxel, or paclitaxel + carboplatin is appropriate
• Creatinine clearance according to Cockcroft-Gault formula : Normal > 80 mL/min, Mild 50-80 mL/min, Moderate 30-<50 mL/min
• A minimum of 4 weeks must have elapsed since the last treatment with other cancer therapies
• Potassium, calcium, magnesium and phosphorus values within the normal range
• Body Mass Index (BMI) must be within the range of 18 and 30

Exclusion Criteria:

• Patients having CNS metastases, must have a CT or MRI of the brain performed to rule out CNS metastases
• Patients with leptomeningeal disease metastases
• Radiotherapy \